|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XX
|
|
gptkbp:brand
|
gptkb:Pemazyre
|
|
gptkbp:casnumber
|
1234567-89-0
|
|
gptkbp:chemical_formula
|
C22 H22 N4 O3 S
|
|
gptkbp:clinical_trial
|
Phase 2
NCT03656536
NCT02924376
NCT03015713
NCT03319711
NCT03319724
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
lactation
|
|
gptkbp:developed_by
|
gptkb:Incyte_Corporation
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
April 17, 2020
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pemigatinib
|
|
gptkbp:indication
|
intrahepatic cholangiocarcinoma
FGFR2 fusion-positive tumors
|
|
gptkbp:interacts_with
|
other FGFR inhibitors
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:marketed_as
|
gptkb:Pemazyre
|
|
gptkbp:mechanism_of_action
|
FGFR inhibitor
|
|
gptkbp:pharmacokinetics
|
metabolized by liver
bioavailability 80%
half-life 13 hours
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
vomiting
decreased appetite
diarrhea
rash
constipation
dry mouth
elevated liver enzymes
|
|
gptkbp:targets
|
FGFR2
|
|
gptkbp:used_for
|
treatment of cholangiocarcinoma
|
|
gptkbp:bfsParent
|
gptkb:Pemazyre
|
|
gptkbp:bfsLayer
|
7
|